The role of Cdc4/Fbw7 in Parkinson's Disease
Cdc4/Fbw7 在帕金森病中的作用
基本信息
- 批准号:7583717
- 负责人:
- 金额:$ 37.98万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-04-01 至 2012-03-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAntioxidantsAutosomal Recesssive Juvenile ParkinsonismBindingBiologyBrainCause of DeathCell ProliferationCessation of lifeCultured CellsDataDefectDevelopmentDiseaseDisease ProgressionDown-RegulationF-Box ProteinsFamilyFunctional disorderGenesHumanInheritedInvestigationJuvenile Parkinson DiseaseKnockout MiceLeadLinkLongevityMalignant - descriptorMediatingMitochondriaModelingMusMutateMutationNeurodegenerative DisordersNeuronsOxidative StressPARK2 geneParkinson DiseasePathologyPhenotypeProtein IsoformsProteinsProteomicsRegulationRoleSyndromeTestingTranscription CoactivatorUbiquitinUbiquitin-Protein Ligase ComplexesWorkbasecopingdopaminergic neuronimprovedinsightknock-downnovel therapeutic interventionparkin gene/proteinpublic health relevanceresearch studyresponseubiquitin ligaseubiquitin-protein ligase
项目摘要
DESCRIPTION (provided by applicant): Parkinson's Disease (PD) is a neurodegenerative disorder associated with selective and progressive death of dopaminergic neurons. Although the cause of death for these neurons is not known, hereditary forms of PD have provided clues. The most frequently mutated gene in autosomal recessive juvenile Parkinsonism (AR-JP) is PARK2, which encodes parkin. Parkin-null mice do not develop PD during their lifespan, but their brains show defects in mitochondrial and antioxidant functions. This and other observations have led to the proposal that death of dopaminergic neurons in human PD is a result of inability to cope with oxidative stress due to mitochondrial and antioxidant dysfunction. Our work with SCFCdc4/Fbw7 has suggested a functional link between this protein-ubiquitin ligase and parkin. Preliminary data suggest that parkin, itself a ubiquitin ligase, targets Cdc4/Fbw7, the rate- limiting component of SCFCdc4/Fbw7, for ubiquitin-mediated destruction. The current proposal explores the potential links between stabilization of Cdc4/Fbw7 in parkin-mutated neurons and the phenotypes associated with parkin mutation, particularly in the context of an SCFCdc4/Fbw7 substrate, the transcriptional co-activator PGC-1. PGC-1 controls mitochondrial and antioxidant function in the brain, and therefore SCFCdc4-dependent PGC-1 downregulation in parkin-mutated brains could account for most if not all of the known parkin-null phenotypes. PUBLIC HEALTH RELEVANCE: Parkinson's disease and related syndromes constitute a set of devastating neurodegenerative disorders. Most inherited Parkinson's disease is characterized by mutations in the PARK2 gene. The current proposal seeks to determine the function of parkin, encoded by the PARK2 gene, in the hope of developing new therapeutic approaches to Parkinson's disease.
描述(由申请人提供):帕金森病(PD)是一种与多巴胺能神经元的选择性和进行性死亡相关的神经退行性疾病。虽然这些神经元的死亡原因尚不清楚,但遗传性PD形式提供了线索。常染色体隐性遗传性青少年帕金森综合征(AR-JP)中最常见的突变基因是PARK 2,它编码parkin。帕金森基因敲除小鼠在其寿命期间不会发生PD,但它们的大脑显示出线粒体和抗氧化功能的缺陷。这一和其他观察结果导致了这样的建议,即人类PD中多巴胺能神经元的死亡是由于线粒体和抗氧化剂功能障碍导致无法科普氧化应激的结果。我们对SCFCdc 4/Fbw 7的研究表明,这种蛋白质-泛素连接酶和parkin之间存在功能联系。初步数据表明,parkin本身是一种泛素连接酶,靶向Cdc 4/Fbw 7,SCFCdc 4/Fbw 7的限速组分,用于泛素介导的破坏。目前的建议探讨了在parkin突变的神经元中Cdc 4/Fbw 7的稳定性与parkin突变相关的表型之间的潜在联系,特别是在SCFCdc 4/Fbw 7底物,转录共激活因子PGC-1的背景下。PGC-1控制着大脑中的线粒体和抗氧化功能,因此帕金森突变大脑中SCFCdc 4依赖性PGC-1下调可以解释大多数(如果不是全部)已知的帕金森无效表型。公共卫生相关性:帕金森病和相关综合征构成了一组破坏性神经退行性疾病。大多数遗传性帕金森病的特征是PARK 2基因突变。目前的提案旨在确定由PARK 2基因编码的parkin的功能,希望开发帕金森病的新治疗方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Steven I Reed其他文献
Steven I Reed的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Steven I Reed', 18)}}的其他基金
Fbw7 as a therapeutic target for treating ischemic brain injury
Fbw7作为治疗缺血性脑损伤的治疗靶点
- 批准号:
8987383 - 财政年份:2015
- 资助金额:
$ 37.98万 - 项目类别:
The SCFFbw7 Substrate Cycle: phosphodegron processing and nucleolar translocation
SCFFbw7 底物循环:磷酸化降解子加工和核仁转位
- 批准号:
8912922 - 财政年份:2015
- 资助金额:
$ 37.98万 - 项目类别:
Fbw7 as a therapeutic target for treating ischemic brain injury
Fbw7作为治疗缺血性脑损伤的治疗靶点
- 批准号:
9063625 - 财政年份:2015
- 资助金额:
$ 37.98万 - 项目类别:
Fbw7 as a therapeutic target for treating ischemic brain injury
Fbw7作为治疗缺血性脑损伤的治疗靶点
- 批准号:
9247857 - 财政年份:2015
- 资助金额:
$ 37.98万 - 项目类别:
The role of Cyclin E in growth control and tumorogenesis
Cyclin E 在生长控制和肿瘤发生中的作用
- 批准号:
8787588 - 财政年份:2014
- 资助金额:
$ 37.98万 - 项目类别:
Fbw7 as a therapeutic target for treating Parkinson's disease
Fbw7作为治疗帕金森病的治疗靶点
- 批准号:
9084633 - 财政年份:2014
- 资助金额:
$ 37.98万 - 项目类别:
Fbw7 as a therapeutic target for treating Parkinson's disease
Fbw7作为治疗帕金森病的治疗靶点
- 批准号:
8786965 - 财政年份:2014
- 资助金额:
$ 37.98万 - 项目类别:
Fbw7 as a therapeutic target for treating Parkinson's disease
Fbw7作为治疗帕金森病的治疗靶点
- 批准号:
8850907 - 财政年份:2014
- 资助金额:
$ 37.98万 - 项目类别:
PHOSPH OF MCM2 BY CDC7 PROMOTES PRC ASSEMBLY DURING CELL-CYCLE RE-ENTRY
CDC7 对 MCM2 的磷酸化促进细胞周期重入期间的 PRC 组装
- 批准号:
8171473 - 财政年份:2010
- 资助金额:
$ 37.98万 - 项目类别:
The role of Cdc4/Fbw7 in Parkinson's Disease
Cdc4/Fbw7 在帕金森病中的作用
- 批准号:
8054203 - 财政年份:2009
- 资助金额:
$ 37.98万 - 项目类别:
相似海外基金
Enhancing gamete cryoprotective properties of graphene oxide by dual functionalization with antioxidants and non-penetrating cryoprotectant molecules
通过抗氧化剂和非渗透性冷冻保护剂分子的双重功能化增强氧化石墨烯的配子冷冻保护特性
- 批准号:
24K18002 - 财政年份:2024
- 资助金额:
$ 37.98万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
SBIR Phase I: Sustainable antioxidants for industrial process fluids
SBIR 第一阶段:工业过程流体的可持续抗氧化剂
- 批准号:
2222215 - 财政年份:2023
- 资助金额:
$ 37.98万 - 项目类别:
Standard Grant
Development of a new bone augmentation method that enables long-term survival and long-term functional expression of transplanted cells by antioxidants
开发一种新的骨增强方法,通过抗氧化剂使移植细胞能够长期存活和长期功能表达
- 批准号:
23K09272 - 财政年份:2023
- 资助金额:
$ 37.98万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Non-Invasive Probing Cellular Oxidative Stress and Antioxidants Therapeutic Effectiveness
非侵入性探测细胞氧化应激和抗氧化剂的治疗效果
- 批准号:
10652764 - 财政年份:2023
- 资助金额:
$ 37.98万 - 项目类别:
Mitochondria-targeting Novel Cationic Hydrazone Antioxidants for the Treatment of Preeclampsia
线粒体靶向新型阳离子腙抗氧化剂用于治疗先兆子痫
- 批准号:
10730652 - 财政年份:2023
- 资助金额:
$ 37.98万 - 项目类别:
Effects of different doses of antioxidants(Vitamin E) intake on exercise induced oxidative stress, antioxidative capacity and chronic inflammation
不同剂量抗氧化剂(维生素E)摄入对运动引起的氧化应激、抗氧化能力和慢性炎症的影响
- 批准号:
22K11609 - 财政年份:2022
- 资助金额:
$ 37.98万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Contribution of antioxidants to regeneration of rotator cuff insertion
抗氧化剂对肩袖插入再生的贡献
- 批准号:
22K16720 - 财政年份:2022
- 资助金额:
$ 37.98万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Latent Antioxidants for Environmentally Responsible Polymer Formulations
用于环保聚合物配方的潜在抗氧化剂
- 批准号:
RGPIN-2018-04107 - 财政年份:2022
- 资助金额:
$ 37.98万 - 项目类别:
Discovery Grants Program - Individual
Polyunsaturated fatty acid (PUFA), inflammation and antioxidants
多不饱和脂肪酸 (PUFA)、炎症和抗氧化剂
- 批准号:
RGPIN-2019-05674 - 财政年份:2022
- 资助金额:
$ 37.98万 - 项目类别:
Discovery Grants Program - Individual
Suppressed methemoglobin formation of artificial red cell by liposomal antioxidants and its mechanism.
脂质体抗氧化剂抑制人工红细胞高铁血红蛋白形成及其机制
- 批准号:
22K12824 - 财政年份:2022
- 资助金额:
$ 37.98万 - 项目类别:
Grant-in-Aid for Scientific Research (C)